Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature

Boigard, Hélène; Cimica, Velasco; Galarza, Jose M.

doi:10.1016/j.vaccine.2018.10.072

Cited by 31 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, in mammalian cells, DEN2 VLPs produced at a lower temperature (31 • C) resembled native dengue viruses. These VLPs also elicited the highest titers of neutralizing antibodies, far exceeding those elicited by VLPs produced at 37 • C [57]. The BacMos system was therefore especially conducive to the production of mosquito cell-derived VLPs at lower temperatures.…”

Section: Discussionmentioning

confidence: 94%

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice

Chang

Chiao

Hsu

et al. 2020

Viruses

View full text Add to dashboard Cite

The Japanese encephalitis virus (JEV) is the major cause of an acute encephalitis syndrome in many Asian countries, despite the fact that an effective vaccine has been developed. Virus-like particles (VLPs) are self-assembled multi-subunit protein structures which possess specific epitope antigenicities related to corresponding native viruses. These properties mean that VLPs are considered safe antigens that can be used in clinical applications. In this study, we developed a novel baculovirus/mosquito (BacMos) expression system which potentially enables the scalable production of JEV genotype III (GIII) VLPs (which are secreted from mosquito cells). The mosquito-cell-derived JEV VLPs comprised 30-nm spherical particles as well as precursor membrane protein (prM) and envelope (E) proteins with densities that ranged from 30% to 55% across a sucrose gradient. We used IgM antibody-capture enzyme-linked immunosorbent assays to assess the resemblance between VLPs and authentic virions and thereby characterized the epitope specific antigenicity of VLPs. VLP immunization was found to elicit a specific immune response toward a balanced IgG2a/IgG1 ratio. This response effectively neutralized both JEV GI and GIII and elicited a mixed Th1/Th2 response in mice. This study supports the development of mosquito cell-derived JEV VLPs to serve as candidate vaccines against JEV.

show abstract

Section: Discussionmentioning

confidence: 94%

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice

Chang

Chiao

Hsu

et al. 2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Hypotheses were given stating that reducing the temperature allowed metabolic processes to be extended and therefore the host organisms could replicate for longer periods of time. Monoclonal antibody titres have also been shown to improve when grown at 31 o C compared to 37 o C (Boigard et al, 2018). Previous work has shown significantly improved yields using an STR over shake flask due to pH and oxygen control.…”

Section: Scale Up Model Evaluation Of the Temperature Kineticsmentioning

confidence: 99%

Improving phage titre through examining point of infection

Ali¹,

Rafiq²,

Ratcliffe³

2020

Preprint

View full text Add to dashboard Cite

Bacteriophages are viruses that cause the lysis of bacteria. They have recently been used to combat antimicrobial resistant infections as an alternative therapy to antibiotics. Their production and propagation, however, remains understudied and will be key to obtaining titres required for future clinical studies and research. Previous work suggests that temperature of infection significantly influences the production process and output yield of phage, with a reduction in temperature from 37ºC to 28ºC resulting in significant increases in productivity for multiple host-phage systems. The current study aimed to build upon this previous work by examining different temperature conditions at the point of infection to determine the effect on harvest phage titre improvements. Investigations were conducted at different culture scales ranging from 20mL shake flasks to 3L stirred tank bioreactor cultures to investigate process differences when scaling from laboratory bench-scale to initial industrial scale fermentations. Additionally, the kinetics of phage infection were investigated. In small scale cultures, the greatest phage bursts and harvest titres were generated by maintaining cultures under static 28 o C incubation during infection compared to agitation and temperature reduction from 37 o C. Investigating the dynamics around the point of infection will help to inform scalable processes for manufacture of phage for a variety of applications ranging from direct therapeutic application to self-assembling bio-templates for nanostructure synthesis.

show abstract

“…When studying dengue VLPs in a mouse model, only VLPs produced at 31 °C, as opposed to 37 °C, were able to generate neutralizing antibodies. [ 59 ] Computational models that study protein folding are recommended to save money and time and ultimately increase the success rate of VLPs becoming candidates for clinical trials. [ 10 ] Despite the difficulties of producing VLPs, VLPs are still considered easier to produce than their native virus.…”

Section: Nanobiomedical Approaches To Covid‐19 Vaccinesmentioning

confidence: 99%

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Lutz

Popowski

Dinh

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVID‐19). The different vaccine types investigated for the prevention of COVID‐19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno‐associated viruses, virus‐like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID‐19 in terms of vaccines and therapeutics.

show abstract

Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature

Cited by 31 publications

References 38 publications

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice

Improving phage titre through examining point of infection

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019

Contact Info

Product

Resources

About